Novo Nordisk A/S $NVO Holdings Decreased by Corient Private Wealth LP

Key Points

• Corient Private Wealth LP reduced its Novo Nordisk stake by 3.5% in the second quarter, selling 23,570 shares and retaining 649,429 shares valued at approximately $31.1 million.
• Other institutional investors, including Invesco, AQR Capital Management and Sivia Capital Partners, increased their positions, while institutional investors collectively own 11.54% of Novo Nordisk.
• Novo Nordisk reported quarterly revenue of $11.98 billion and earnings per share of $0.94. Analysts maintain a consensus “Hold” rating, with sentiment influenced by potential growth from Wegovy’s China expansion and concerns about competition and the semaglutide patent cliff.

Corient Private Wealth LP lessened its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 3.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 649,429 shares of the company's stock after selling 23,570 shares during the period. Corient Private Wealth LP's holdings in Novo Nordisk A/S were worth $31,134,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Revolve Wealth Partners LLC increased its stake in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after acquiring an additional 200 shares during the period. AQR Capital Management LLC lifted its position in Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company's stock worth $4,312,000 after purchasing an additional 10,758 shares during the period. Sivia Capital Partners LLC boosted its stake in Novo Nordisk A/S by 18.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company's stock valued at $712,000 after purchasing an additional 1,587 shares in the last quarter. Invesco Ltd. boosted its stake in Novo Nordisk A/S by 26.3% during the 2nd quarter. Invesco Ltd. now owns 419,691 shares of the company's stock valued at $28,967,000 after purchasing an additional 87,467 shares in the last quarter. Finally, Gamco Investors INC. ET AL acquired a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at $314,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $43.03 on Monday. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $64.16. The firm's 50 day simple moving average is $47.49 and its 200-day simple moving average is $43.68. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66. The company has a market cap of $192.15 billion, a P/E ratio of 10.52, a price-to-earnings-growth ratio of 1.45 and a beta of 0.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. The firm had revenue of $11.98 billion for the quarter. As a group, equities research analysts predict that Novo Nordisk A/S will post 3.45 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were issued a dividend of $0.5786 per share. The ex-dividend date was Monday, August 17th. This represents a dividend yield of 258.0%. Novo Nordisk A/S's payout ratio is currently 20.05%.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy received approval in China for MASH, making it the first GLP-1 receptor agonist in the country approved for the liver disease. The decision expands semaglutide’s potential beyond obesity and diabetes, although Novo has not provided a launch schedule or revenue outlook. Reuters article
• Positive Sentiment: China’s acceptance of Novo’s oral Wegovy application creates a potential avenue into the country’s growing GLP-1 weight-management market. Investors see the opportunity as a possible long-term growth driver, though regulatory approval, launch timing and competitive dynamics remain uncertain. Oral Wegovy China article
• Neutral Sentiment: HSBC raised its price target to 320 Danish kroner but kept a Hold rating, reflecting improved valuation expectations without a strong near-term conviction. HSBC price target article
• Positive Sentiment: Some analysts continue to view Novo’s valuation, strong margins, free cash flow and GLP-1 leadership as providing a margin of safety, suggesting the recent weakness may already reflect substantial execution and competitive risks. Novo Nordisk valuation analysis
• Negative Sentiment: The Morgan Stanley downgrade is the dominant near-term catalyst. Investors are questioning whether oral Wegovy, China expansion and other pipeline opportunities can replace revenue exposed to the semaglutide patent cliff, contributing to NVO’s decline and keeping sentiment weak. Morgan Stanley downgrade article

Analyst Upgrades and Downgrades

A number of analysts have recently commented on NVO shares. Citigroup reissued a "neutral" rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Berenberg Bank set a $47.00 target price on Novo Nordisk A/S in a report on Wednesday, August 12th. HSBC reiterated a "hold" rating on shares of Novo Nordisk A/S in a research report on Thursday. Wall Street Zen downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, June 20th. Finally, Zacks Research upgraded shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Novo Nordisk A/S currently has a consensus rating of "Hold" and a consensus price target of $64.94.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.